Barclays has initiated coverage on Xeris Biopharma Holdings Inc (XERS) with an Overweight rating as of December 8, 2025. This marks the firm's first assessment of the biopharmaceutical company, which is headquartered in Chicago, Illinois.
Xeris Biopharma focuses on developing and commercializing products across a range of therapies, including three commercially available products: Recorlev, Gvoke, and Keveyis. The company has a market capitalization of $1.2 billion and an earnings per share (EPS) of -0.21 for the trailing twelve months.
Upcoming earnings reports are scheduled for May 6, 2026, with an estimated EPS of $0.00 and revenue of $84.9 million, followed by another report on August 5, 2026, with an EPS estimate of $0.04 and revenue of $94.5 million.
Analyst ratings and price targets are based on research and financial models, reflecting professional opinions that should be considered alongside company fundamentals and market conditions. As of December 1, 2025, the analyst consensus for XERS includes 5 Strong Buy, 5 Buy, and 2 Hold ratings, with a consensus rating of Buy.
The move underscores Barclays' confidence in Xeris Biopharma's growth potential amidst its ongoing development programs, including XP-8121, a phase III-ready treatment for hypothyroidism. Analyst views may evolve as new data becomes available, highlighting the dynamic nature of market assessments.